Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
  1. Sep 5, 2024The success of cancer immunotherapy can be limited by mechanisms that tumors develop to evade destruction by the immune system. Tumors can block the activation and obstruct the ability of immune cells (dendritic cells and T lymphocytes) to destroy the tumor, thereby creating an environment that is beneficial for cancer growth.
    • Download PDF

      RESEARCH ARTICLE IMMUNE ENGINEERING In vivo dendritic cell reprogramming for cancer immunotherapy Ervin Ascic 1,2, Fritiof Åkerström3, Malavika Sreekumar Nair , André Rosa3, Ilia Kurochkin1,2, Olga Zimmermannova1,2, Xavier Catena1,2,3, Nadezhda Rotankova4, Charlotte Veser 4, Michal Rudnik , Tommaso Ballocci1,2, Tiffany Schärer 3, Xiaoli Huang , Maria de Rosa Torres1,2, Emilie Renaud3,

  2. pubmed.ncbi.nlm.nih.gov

    Oct 18, 2024Immunotherapy can lead to long-term survival for some cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral deli …
  3. pmc.ncbi.nlm.nih.gov

    Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy. ... and Nordic Biolabs. Detailed information on cells used in the study and culture conditions are ... Major histocompatibility complex class II presentation of cell-associated antigen is mediated by CD8α+ dendritic cells in vivo. J ...
  4. Sep 5, 2024RESEARCH ARTICLE IMMUNE ENGINEERING In vivo dendritic cell reprogramming for cancer immunotherapy Ervin Ascic 1,2, Fritiof Åkerström3, Malavika Sreekumar Nair , André Rosa3, Ilia Kurochkin1,2, Olga Zimmermannova1,2, Xavier Catena1,2,3, Nadezhda Rotankova4, Charlotte Veser 4, Michal Rudnik , Tommaso Ballocci1,2, Tiffany Schärer 3, Xiaoli Huang , Maria de Rosa Torres1,2, Emilie Renaud3,
  5. orbit.dtu.dk

    Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy. Original language: English: Article number: eadn9083: Journal: Journal of Bio-X Research: Volume: 386: Issue number: 6719: Number of pages: 17: ... In vivo dendritic cell reprogramming for cancer immunotherapy. / Ascic, Ervin ...
  6. oncodaily.com

    Sep 6, 2024Find the study here.. In this study, we demonstrated that reprogramming tumor cells in vivo within the immunosuppressive tumor microenvironment (TME) into type 1 conventional dendritic cells (cDC1s) enabled them to efficiently present tumor antigens and elicit systemic and safe antitumor immunity, showcasing a new immunotherapy modality for cancer.. We have previously demonstrated that cancer ...
  7. sciencedirect.com

    Aug 1, 2024In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo.
  8. Oct 17, 2024In vivo dendritic cell reprogramming for cancer immunotherapy. By Ervin Ascic, Fritiof Åkerström, ... manipulating DCs is a promising strategy for cancer immunotherapy. ... both the in situ reprogramming of cancer cells into cDC1-like cells and their antitumor function were unaffected by the immunosuppressive TME in the spheroids . This is ...
  9. read.qxmd.com

    In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for human clinical trials of in vivo immune cell reprogramming for cancer immunotherapy.
  10. Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX